J&J-related uncertainties are behind us now
11/03/25 -"Yesterday, J&J announced it would not exercise its option to license HexaBody-CD38 (previously deemed to be Darzalex’s successor) from Genmab, thereby ending the uncertainty around this ..."
Pages
46
Language
English
Published on
11/03/25
You may also be interested by these reports :
27/02/26
The Q4 results were ahead of consensus, but a lack of 2026 sales guidance casts doubt over Grifols’ ability to deliver on its 2029 sales and ...
27/02/26
The Q4 sales exceeded expectations, though ‘adjusted’ EBITDA was somewhat behind the consensus. The Q4 performance was driven by LatAm, Animal ...
26/02/26
Even though the H2 25 results were ahead of consensus, the 2026 outlook was below the street’s expectations. While Branded posted strong H2 growth, ...
26/02/26
Novonesis stumbled at the finish line — Q4 25 revenue and EBITDA missed consensus by 2.3% and 2.9% respectively, dragged down by weakness in the ...